Literature DB >> 27530185

Do antipsychotics lead to cognitive impairment in dementia? A meta-analysis of randomised placebo-controlled trials.

Alexander Wolf1, Stefan Leucht2, Frank-Gerald Pajonk3.   

Abstract

Behavioural and psychological symptoms in dementia (BPSD) are common and often treated with antipsychotics, which are known to have small efficacy and to cause many side effects. One potential side effect might be cognitive decline. We searched MEDLINE, Scopus, CENTRAL and www.ClincalStudyResult.org for randomized, double-blind, placebo-controlled trials using antipsychotics for treating BPSD and evaluated cognitive functioning. The studies identified were summarized in a meta-analysis with the standardized mean difference (SMD, Hedges's g) as the effect size. Meta-regression was additionally performed to identify associated factors. Ten studies provided data on the course of cognitive functioning. The random effects model of the pooled analysis showed a not significant effect (SMD = -0.065, 95 % CI -0.186 to 0.057, I 2 = 41 %). Meta-regression revealed a significant correlation between cognitive impairment and treatment duration (R 2 = 0.78, p < 0.02) as well as baseline MMSE (R 2 = 0.92, p < 0.005). These correlations depend on only two out of ten studies and should interpret cautiously.

Entities:  

Keywords:  Antipsychotics; Cognition; Dementia; Meta-analysis

Mesh:

Substances:

Year:  2016        PMID: 27530185     DOI: 10.1007/s00406-016-0723-4

Source DB:  PubMed          Journal:  Eur Arch Psychiatry Clin Neurosci        ISSN: 0940-1334            Impact factor:   5.270


  47 in total

Review 1.  Management of aggression, agitation, and psychosis in dementia: focus on atypical antipsychotics.

Authors:  Peter Aupperle
Journal:  Am J Alzheimers Dis Other Demen       Date:  2006 Mar-Apr       Impact factor: 2.035

2.  A double-blind comparison of olanzapine versus risperidone in the acute treatment of dementia-related behavioral disturbances in extended care facilities.

Authors:  Catherine S Fontaine; Linda S Hynan; Kathleen Koch; Kristin Martin-Cook; Doris Svetlik; Myron F Weiner
Journal:  J Clin Psychiatry       Date:  2003-06       Impact factor: 4.384

3.  Cognitive effects of atypical antipsychotic medications in patients with Alzheimer's disease: outcomes from CATIE-AD.

Authors:  Cheryl L P Vigen; Wendy J Mack; Richard S E Keefe; Mary Sano; David L Sultzer; T Scott Stroup; Karen S Dagerman; John K Hsiao; Barry D Lebowitz; Constantine G Lyketsos; Pierre N Tariot; Ling Zheng; Lon S Schneider
Journal:  Am J Psychiatry       Date:  2011-05-15       Impact factor: 18.112

4.  Efficacy and adverse effects of atypical antipsychotics for dementia: meta-analysis of randomized, placebo-controlled trials.

Authors:  Lon S Schneider; Karen Dagerman; Philip S Insel
Journal:  Am J Geriatr Psychiatry       Date:  2006-03       Impact factor: 4.105

5.  Comparison of risperidone with olanzapine in elderly patients with dementia and psychosis.

Authors:  Vicki L Ellingrod; Susan K Schultz; Karen Ekstam-Smith; Eric Kutscher; Carolyn Turvey; Stephan Arndt
Journal:  Pharmacotherapy       Date:  2002-01       Impact factor: 4.705

6.  Quetiapine treatment of psychosis associated with dementia: a double-blind, randomized, placebo-controlled clinical trial.

Authors:  Pierre N Tariot; Lon Schneider; Ira R Katz; Jacobo E Mintzer; Jamie Street; Margaret Copenhaver; Celeste Williams-Hughes
Journal:  Am J Geriatr Psychiatry       Date:  2006-08-11       Impact factor: 4.105

7.  The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: a review and meta-analysis.

Authors:  R S Keefe; S G Silva; D O Perkins; J A Lieberman
Journal:  Schizophr Bull       Date:  1999       Impact factor: 9.306

8.  Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer disease in nursing care facilities: a double-blind, randomized, placebo-controlled trial. The HGEU Study Group.

Authors:  J S Street; W S Clark; K S Gannon; J L Cummings; F P Bymaster; R N Tamura; S J Mitan; D L Kadam; T M Sanger; P D Feldman; G D Tollefson; A Breier
Journal:  Arch Gen Psychiatry       Date:  2000-10

9.  Putting the Alzheimer's cognitive test to the test II: Rasch Measurement Theory.

Authors:  Jeremy Hobart; Stefan Cano; Holly Posner; Ola Selnes; Yaakov Stern; Ronald Thomas; John Zajicek
Journal:  Alzheimers Dement       Date:  2012-12-17       Impact factor: 21.566

10.  Antipsychotic drug use and mortality in older adults with dementia.

Authors:  Sudeep S Gill; Susan E Bronskill; Sharon-Lise T Normand; Geoffrey M Anderson; Kathy Sykora; Kelvin Lam; Chaim M Bell; Philip E Lee; Hadas D Fischer; Nathan Herrmann; Jerry H Gurwitz; Paula A Rochon
Journal:  Ann Intern Med       Date:  2007-06-05       Impact factor: 25.391

View more
  3 in total

Review 1.  Drug interactions with dementia-related pathophysiological pathways worsen or prevent dementia.

Authors:  Romain Barus; Johana Béné; Julie Deguil; Sophie Gautier; Régis Bordet
Journal:  Br J Pharmacol       Date:  2019-03-31       Impact factor: 8.739

Review 2.  Treatment of behavioral and psychological symptoms of dementias with psychopharmaceuticals: a review.

Authors:  Jiří Masopust; Dita Protopopová; Martin Vališ; Zbyšek Pavelek; Blanka Klímová
Journal:  Neuropsychiatr Dis Treat       Date:  2018-05-09       Impact factor: 2.570

3.  Interrupting the trajectory of frailty in dementia with Lewy bodies with anabolic exercise, dietary intervention and deprescribing of hazardous medications.

Authors:  Michael Inskip; Yorgi Mavros; Perminder Singh Sachdev; Maria A Fiatarone Singh
Journal:  BMJ Case Rep       Date:  2020-04-26
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.